A group of scientists from the University of Barcelona has presented a new experimental drug, FLAV-27, which has demonstrated the ability to restore memory in mice suffering from Alzheimer's disease. The findings of this research were published in the journal Molecular Therapy, reported the agency Lenta.Ru.
Unlike traditional medications that focus on removing beta-amyloid plaques, FLAV-27 targets deeper aspects by regulating gene activity in neurons. This drug works through an epigenetic mechanism, blocking the enzyme G9a, which under disease conditions reduces the activity of genes responsible for memory and the formation of neural connections. The reduction of G9a activity allows neurons to function more effectively, leading to the restoration of memory processes.
Animal experiments showed that the drug not only reduces the accumulation of pathological proteins such as beta-amyloid and tau but also contributes to significant improvements in cognitive functions. Mice showed restoration of both short-term and long-term memory, improved spatial orientation and social behavior, and the structure of synapses in the brain approached normal levels.
Adelya Klycheva
